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Abstract: A bone graft has been the gold standard treatment for repairing bone defects. However, due to bone grafts 
associated donor site morbidity several alternative bone substitutes options have been made available but with their added 
expense and limited osteoinductive properties they are not ideal. Therefore, research has begun in tissue engineering to 
investigate stem cells, which are one of the body’s own mechanisms used to repair bone. Stem cells are clonogenic 
undifferentiated cells capable of self-renewal. Readily available from numerous of sources stem cells have the potential to 
differentiate in osteoblasts and chrondrocytes showing capability to repair both bone and cartilage. The known 
immunologic properties of stem cells further enhance their therapeutic appeal. Stem cells have shown to be excellent 
carriers for gene transfer having the capability to be transduced. Gene transfer could enable growth factors and bone 
morphogentic proteins to enhance bone repair. Stem cells are implanted onto scaffolds, which are structures capable of 
supporting tissue formation by allowing cell migration, proliferation and differentiation. Research aims to produce 
scaffolds that deliver and retain cells, allow for cell attachment has adequate biodegradability, biocompatibility and non-
immunogenicity. However, having tried and testing numerous materials including synthetic and natural products research 
into the perfect scaffold product continues. This review aims to explain how stem cells were discovered, the techniques 
used to isolate stem cells, identify and manipulate them down different cell lineages and discuss the research into using 
stem cells to reconstruct bone using genetic modification and scaffolds. 
Keywords: Adult stem cells, bone marrow, bone reconstruction, gene therapy, scaffolds, tissue engineering. 
  Bone defects exceeding critical size usually heal with 
fibrous tissue (scar), missing complete bone re-union. The 
critical size is defined as intraosseous deficiency that will not 
heal with more than 10% new bone formation within life 
expectancy of the patient (human or nonhuman) [1]. 
  Reconstruction of bone defects is dependent on certain 
mechanisms, which can be summarized into osteoconduct-
ion, osteoinduction and osteogenesis mechanisms. Osteo-
genesis is the formation of new bone from osteocompetent 
cells. Osteoconduction is the formation of bone along the 
scaffold of a biologic or alloplastic substance where the bone 
forming cells originate from pre-existing host osteo-
competent cells. Osteoinduction is the formation of new 
bone by differentiation and stimulation of mesenchymal cells 
by bone inductive proteins [2]. 
  In principle, bone grafts contain all the key elements 
required for bone repair; as they provide osteoconductive 
scaffold, growth factors for osteoinduction, and cells with 
osteogenic potential  [3]. The use of bone grafts in the   
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clinical practice presents several major inconveniences [4]. 
Although the percentage of success is high, complications as 
resorption, fracture, infection and non-union are still present 
[5]. Additionally harvesting of autologous bone often results 
in donor site morbidity, the extent of which may vary 
according to the location and the intervention technique 
including hemorrhage, nerve damage, cosmetic disability, 
pain, infection, and loss of function [6]. 
  The use of human cadaver or animal bone grafts from 
bone banks prevents the problem of the donor site morbidity, 
but presents the potential risk of viral or bacterial infections 
and an immune response of the host tissue towards the 
implant. However, the continuous amelioration of the 
processing procedures for grafts is significantly reducing the 
risk of infection [7]. 
  Alternatively, guided bone regeneration and several 
biomaterials have been considered and used as bone 
substitutes, including calcium phosphate ceramics, polymers 
and bioglasses. All have the advantage of unlimited 
availability and good osteoconductive properties. On the 
other hand, they are not osteoinductive, thus limiting their 
application to repair large bone defects [8]. On the contrary, 
bone distraction takes the advantage of bone regeneration 
potential; avoiding the troubles associated with the graft 290    The Open Orthopaedics Journal, 2011, Volume 5  Khaled et al. 
integration. However, it is highly problematic for the 
patients, technically demanding method and requires long 
interval to be completed [9]. 
  Bone tissue engineering can guarantee unlimited source 
for bone regeneration without complications of other bone 
reconstruction modalities. Also, this technique is of great 
advantage in bone reconstruction in case of huge bone 
defects and in pediatric population; because of limited 
autogenous bone reservoir in addition to restricted use of 
alloplastic materials; because of ongoing skeletal growth 
[10]. 
WHAT ARE STEM CELLS? 
  The history of stem cells began in 1976, when certain 
cells were isolated and cultured, the product of this culture 
were adherent fibroblast like cells capable of proliferation 
and differentiation into bone and cartilage like colonies. 
These cells were given the name “colony forming unit- 
fibroblast (CFU-F). Later on, these cells were named 
mesenchymal stem cells (1994), marrow stromal cells (1997) 
and mesenchymal progenitor cells (1999). Nowadays, the 
mesenchymal stem cell (MSC) is the most popular 
dominator given to these cells [3]. 
  Stem cells are defined as clonogenic undifferentiated 
cells capable of self-renewal and differentiation into one or 
more cell progenies. Historically, adult MSCs were thought 
to be developmentally restricted to specific cell lineages that 
are related to the tissue in which the cells reside. Now, it is 
proven that the differentiation potential of adult MSCs is 
very versatile including all mesenchymal derived tissues. 
Moreover, under the appropriate conditions adult MSCs have 
the potential to transdifferentiate into cells possessing 
morphological and biochemical properties of ectodermal 
derived neural tissue, as well as dedifferentiation into 
pluripotent stem cell. The transdifferentiation property of 
adult MSCs was certified through detection of a myriad of 
neural markers in vitro, including nestin, mitogen-activated 
protein 2, Tau, NeuN, and glial ﬁbrillary acidic protein [3]. 
  To date, stem cells have been isolated and characterized 
from embryonic, fetal, and adult tissues. Embryonic stem 
(ES) cells are pluripotent, and are capable of unlimited 
proliferation in an undifferentiated state. Embryonic stem 
cells are totally uncommitted cells which need certain cell 
programming to be directed into specific cell progeny. The 
fetal stem cells are an intermediate cell type between ES and 
the adult stem cells. Adult stem cells are highly committed 
cells which need some reprogramming to differentiate into 
mature tissues [11]. 
  Adult stem cells are the cornerstone stem cell model used 
in recent research; as it minimize the ethical and legal 
debates. Adult stem cells are all postnatal stem cells which 
can be classified into hematopoietic stem cells, epithelial 
stem cells and MSCs. Unlike the two other sources of adult 
stem cells; adult MSCs are more superior as they can be 
isolated from multiple sources like bone marrow, adipose 
tissue, periosteum, muscle, dermis, synovial membranes, etc. 
Also adult MSCs are multipotent cells capable of 
differentiation into a variety of mature tissues [3]. 
 
 
THE IDEAL SOURCE OF ADULT STEM CELLS 
  Bone marrow is a major source for osteogenic cells 
capable of forming bones in vitro. However, cell isolation 
procedure from bone marrow occasionally causes some 
disadvantages in clinical practice. Bone marrow aspiration is 
potentially more invasive and painful procedure, and it 
increases a risk of morbidity and infection. In addition to 
bone marrow-derived MSCs, periosteal-derived cells are also 
multipotent and have the potential to differentiate into 
osteoblasts and chondrocytes. Periosteal-derived cells have 
several advantages in comparison with bone marrow-derived 
MSCs, such as a minimal invasion to obtain cells, and easy 
cell harvest. These periosteal-derived cells also retain the 
property to differentiate into osteoblasts after following 
enzyme treatment and cell expansion [12]. 
  An ideal source of autologous stem cells would, therefore, 
be both easy to obtain, result in minimal patient discomfort, yet 
be capable of yielding cell numbers substantial enough to 
obviate extensive expansion in culture. Adipose tissue, like 
bone marrow, is derived from the embryonic mesoderm and 
contains a heterogenous stromal cell population. These 
similarities make the concept that a stem cell population can be 
isolated from human adipose tissue. Moreover, the 
disadvantages of traditional bone marrow harvesting procedures 
in addition to low numbers of MSCs upon processing which 
necessitate an ex vivo expansion step to obtain clinically 
significant cell numbers. Such a step is time consuming, 
expensive, and risks cell contamination and loss. All these 
points of comparison make the adipose derived stem cell better 
source for stem cells [13]. 
STEM CELLS IDENTIFICATION 
  Identification of stem cells is achieved through their 
morphology, phenotypic characteristics and their biological 
behavior. Morphologically, stem cells are spindle shaped 
cells with central large nucleus, multiple cytoplasmic 
processes usually project from the outer surface. To date, 
there is no specific phenotypic marker to identify stem cells. 
However, stem cells are capable of expressing a lot of 
surface markers, these markers have also been detected in 
mesenchymal, endothelial, or epithelial cells. In conclusion, 
the stem cells can only be identified with their biological 
behavior as cells capable of proliferation and differentiation 
into different cell progenies [13]. 
  Being one of the most popular sources of stem cells, 
research activities focused on the identification of bone 
marrow derived adult MSCs through three markers CD34, 
CD45, and CD90. CD34 is a surface marker of 
hematopoietic progenitors, CD45 is a lymphocytic surface 
marker, and CD90 is the major surface marker of 
mesenchymal cells [14]. We have previously shown that 
passage 2 synovial fat pad derived MSCs and bone marrow 
derived MSCs stained strongly for CD13, CD29, CD44, 
CD90 and CD105, and poorly for LNGFR, STRO1, CD34 
and CD56 (Fig. 1). Occasional cells stained positively for 
3G5 from both the synovial fat pad and bone marrow. 
  Although the molecular mechanisms governing MSC 
differentiation are not completely understood, a number of  
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Fig. (1). Cell surface epitope characterisation of passage 2 synovial fat pad derived MSCs (a) and bone marrow derived MSCs (b) using a 
panel of antibodies. Cell surface staining using FITC conjugated secondary antibody (green) and DAPI (blue) shows that the cells stained 
strongly for CD13, CD29, CD44, CD90 and CD105, and poorly for LNGFR, STRO1, CD34 and CD56. Occasional cells stained positively 
for 3G5 from both the synovial fat pad and bone marrow. No staining was observed for the IgG control.  292    The Open Orthopaedics Journal, 2011, Volume 5  Khaled et al. 
growth factor mediated signaling pathways have been shown 
to induce or regulate the differentiation of MSCs along 
mesenchymal lineages as Bone morphogenic protiens (BMP) 
and ﬁbroblast growth factor (FGF) are examples for these 
growth factors [15]. 
WHY STEM CELLS ARE NOT IMMUNOGENIC? 
  Ultimately, the immunology of MSCs, similar to many 
other aspects of these cells, remains poorly defined. Well-
designed  in vivo studies of the immunogenicity and the 
immune-modulatory capacity of MSCs in specific 
pathophysiologic models are needed before further claims 
regarding the immune properties of MSCs can be made. The 
known immunologic properties of MSCs enhance their 
therapeutic appeal. However, as with most analysis of 
MSCs, these immune properties have been observed 
exclusively on cultured cells. The immune phenotype of 
cultured MSCs is widely described as MHC Class I +ve, 
MHC Class II -ve, CD40 -ve, CD80 -ve, and CD86 –ve [16, 
17]. 
  This phenotype is regarded as non-immunogenic and 
suggests that MSCs might be effective in inducing tolerance. 
Class I may activate alloreactive T cells, but with the 
absence of co-stimulatory molecules, a secondary signal 
would not engage, leaving the T cells anergic [18]. MSCs are 
able to inhibit production of cytotoxic lymphocytes in vitro 
and resist killing by both cytotoxic lymphocytes and natural 
killer cells. Also MSCs are proved to inhibit peripheral blood 
mono-nuclear cells (PBMCs) even if external co-stimulatory 
molecules are added. This was explained presumably 
through soluble factors production [17]. Once again, there is 
a surprising lack of data on the immunomodulatory effects of 
MSCs  in vivo. It was reported that MSCs have prolonged 
allogeneic skin graft survival in immunocompetent, outbred 
baboons [19]. 
BONE TISSUE ENGINEERING 
  Tissue engineering is an emerging interdisciplinary field 
that applies principles of both life sciences and engineering 
towards the development of biological substitutes that 
restore, maintain, and improve function of damaged and/or 
lost tissues  [3, 20]. Tissue engineering is now occupying 
front position in regenerative medicine field. Specially, after 
emerging of another class of tissue engineering which is the 
cell based tissue engineering; where structural and functional 
defects are completely restored. This achieves the superior 
aim of regenerative medicine by substitution of missed 
tissues with the same type of tissue [20]. The various types 
are described below. 
1. Local Recruitment of Osteogenic Cells 
  An important progress in treating bone defects has been 
the introduction of bone morphogenetic proteins (BMPs) 
specifically BMP-2, BMP-4 and BMP-7. These proteins 
induce osteogenic cell differentiation in vitro, as well as 
bone defect healing in vivo. Carriers enhancing the binding 
of BMPs are of the most importance, since extended BMP 
release creates an osteogenic microenvironment that allows 
multipotent cell progenitors to migrate to the area of injury 
and to proliferate and differentiate toward the osteogenic 
lineage. The four major categories of BMP carrier materials 
are natural polymers, inorganic materials, synthetic polymers 
and composites of these materials [3]. 
  This, however will fail if the vitality and the number of 
the patient’s multipotent cells are insufficient or if the patient 
is aged and with a poor general health status. The last 
condition includes patients with large bone defects, who 
underwent radiation or chemotherapy, elderly, 
immunocompromized, malnourished patients and other. 
Milligrams of BMPs are problematic as regards 
manufacturing, cost and dose [1,3]. 
2. Gene Therapy and Tissue Engineering 
  MSCs have also shown great promise in the delivery of 
genes or gene products. The ability of MSCs to be 
transduced gives them the potential to serve as vehicles or 
either long-term or short-term therapeutic gene transfer, for 
instance, as in expressing BMP for bone repair. BMP 
transduced bone marrow derived stem cells have shown 
effective power in repair of critical sized defects in different 
animal models and different sites [21]. 
  On the other hand, the administration of supra-
physiological doses of BMP has been shown to induce the 
opposite effect by stimulating bone resorption and turnover, 
yielding a counter productive response. Therefore, utilizing 
MSCs as a BMP delivery vehicle may ensure the site-
specific administration of physiological doses of BMP [22]. 
3. In Vitro Osteoinduction of Stem Cells 
  Osteoinductive cytokines is added to the routine culture 
media in order to control stem cells differentiation towards 
osteoblast lineage. Among the most popular induction 
protocols is the combination of -glycerophosphate, dexa-
methasone and ascorbic acid. Where -glycerophosphate is a 
source for organic phosphate, dexamethasone is crucial in 
expression of osteogenic phenotype in certain concen-
trations, and ascorbic acid important in collagen and mineral 
deposition. Other osteoinductive growth factors and 
cytokines include transforming growth factor  (TGF- 1), 
fibroblast growth factor (FGF), active vitamin D, BMPs 
(BMP 2, 4 and 7) and parathyroid hormone [13]. 
  It is known that osteoblastic differentiation from 
undifferentiated state to functional active osteoblast is a 
series of steps involving a number of proteins expressed at 
each stage, such as Alkaline Phosphatase (ALP), osteocalcin 
and mineral deposition. In general, ALP is considered as a 
relatively early marker of osteoblast differentiation. During 
the bone formation, the extracellular matrix progressively 
assumes bone-like properties and then, with the onset of 
mineralization, there is an increased activity of non-
collagenous extracellular matrix protein, such as osteocalcin, 
and deposition of inorganic crystals composed of calcium 
and phosphate. At the end, loading of a suitable scaffold with 
induced cells hand in hand with incubation of the whole 
culture in bioreactor provide efficient but expensive way to 
generate bone [12]. 
4. Ex-Vivo Production of Tissue Engineered Bone 
  The stem cell-based tissue engineering of bone includes 
three main steps. First, stem cell harvesting, isolation and 
expansion. Secondly, scaffold seeding with induced stem 
cells. Finally, re-implantation is done in vivo to reconstruct a Cell Surface Characterisation  The Open Orthopaedics Journal, 2011, Volume 5    293 
defect. This field has received a great deal of attention owing 
to its affinity as an alternative to bone grafts and substitutes 
for reconstruction of bone [9]. 
WHAT IS A SCAFFOLD? 
  Stem cells are often implanted or seeded into a structure 
capable of supporting three-dimensional tissue formation. 
These structures, typically called scaffolds, are often critical, 
both ex vivo as well as in vivo, to recapitulating the in vivo 
milieu and allowing cells to influence their own micro-
environments. Tissue engineering approaches to skeletal 
reconstruction evoke the general principles of using porous 
scaffolds that deliver biofactors (cells, genes and proteins) to 
regenerate natural tissue. Scaffolds must also meet the 
typical requirements for mechanically functioning tissues of 
enhancing tissue regeneration through biofactor delivery 
while maintaining temporary mechanical function until the 
tissue can bear load. However, in certain areas of 
reconstruction (e.g. craniofacial); scaffolds must fit very 
complex three-dimensional (3D) anatomic defects that can 
be much more complicated than those in the appendicular 
skeleton [23]. 
BASIC REQUIREMENTS FOR SCAFFOLDS 
  Scaffolds should fit complex 3D anatomic defects. This 
can be achieved roughly through surgical experience in 
designing or highly sophisticated computed designing 
systems [24]. They should provide temporary load bearing 
skeleton until neo-tissue forms. Biodegradability is often an 
essential factor since scaffolds should preferably be absorbed 
by the surrounding tissues without the necessity of a surgical 
removal. The rate at which degradation occurs has to 
coincide as much as possible with the rate of tissue 
formation: this means that while cells are fabricating their 
own natural matrix structure around themselves, the scaffold 
is able to provide structural integrity within the body and 
eventually it will break down leaving the neo-tissue, newly 
formed tissue which will take over the mechanical load [25]. 
  Scaffolds should enhance tissue regeneration through 
biofactor delivery. To achieve the goal of tissue 
reconstruction, scaffolds must be porous with adequate pore 
size; to facilitate cell seeding and diffusion throughout the 
whole structure of both cells and nutrients. Porosity ranged 
from 300–1200m diameter is efficient in supporting cell 
migration, proliferation and growth factor transport. Smaller 
diameter porosity is not efficient while larger one can affect 
mechanical properties of the scaffold. So coupling of both, 
scaffold load bearing properties and porosity is of a 
paramount importance in having ideal scaffold. Both 
requirements are variable according to the area under the 
interest of reconstruction purposes [23]. 
TYPES OF SCAFFOLDS 
  Many different materials (natural and synthetic, 
biodegradable and permanent) have been investigated. Most 
of these materials have been known in the medical field 
before the advent of tissue engineering as a research topic, 
being already employed as bioresorbable sutures. Examples 
of these materials are collagen and some polyesters. New 
biomaterials have been engineered to have ideal properties 
and functional customization: injectability, synthetic 
manufacture, biocompatibility, non-immunogenicity, trans-
parency, nano-scale fibers, resorption rates, etc [26]. 
  There are broadly two groups of scaffolds and scaffolds 
from natural materials are the first group. In particular 
different derivatives of the extracellular matrix have been 
studied to evaluate their ability to support cell growth. 
Proteic materials, such as collagen or fibrin, and 
polysaccharidic materials, like chitosan or glycosaminog-
lycans (GAGs), have all proved suitable in terms of cell 
compatibility, but some issues with potential immuno-
genicity still remains. Among GAGs, hyaluronic acid, 
possibly in combination with cross linking agents (e.g. 
glutaraldehyde, water soluble carbodiimide etc), is one of the 
possible choices as scaffold material [26]. Also placental 
decellular matrix (PDM) was evaluated by Flynn and his 
coworkers as regards its effect on seeded cells activity [25]. 
Natural coral with a pore size of 150 to 220 μm and porosity 
of about 36% was molded into the shape of a human 
mandibular condyle. This Coral gives significant results as a 
scaffold in addition to recombinant human bone 
morphogenetic protein-2 (rhBMP-2) [24]. 
  The second group is synthetic scaffolds, and a commonly 
used synthetic material is PLA- polylactic acid. This 
polyester which degrades within the human body to form 
lactic acid, a naturally occurring chemical which is easily 
removed from the body. Similar materials are polyglycolic 
acid (PGA) and polycaprolactone (PCL), their degradation 
mechanism is similar to that of PLA, but they exhibit 
respectively a faster and a slower rate of degradation 
compared to PLA [26]. Researches aim at creating scaffold 
materials with biomimetic properties that would mimic the 
role of the extracellular matrix (ECM) in many cell 
functions, including: adhesion, migration. Further 
engineering of biomaterial surface and bulk properties will 
allow bio-specific interactions between appropriate cell types 
and scaffold materials and proliferation. Porosity is one of 
the essentials for successful scaffolding materials. A number 
of different methods have been described in literature for 
preparing porous structures to be employed as tissue 
engineering scaffolds. Each of these techniques presents its 
own advantages, but none is devoid of drawbacks [26]. 
DISCUSSION 
  The Craniofacial, Maxillofacial, upper and lower limb 
reconstructive procedures often require bone graft 
harvesting, which results in donor site morbidity. The Cell 
based tissue engineering is the cornerstone technique in 
tissue regeneration; especially in bone production. Bone 
tissue engineering overcomes the drawbacks of the common 
techniques of bone reconstruction [6]. 
  Bone tissue engineering is considered as an unlimited 
source of bone production without donor site morbidity and 
other autogenous bone grafting restrictions. There is no risk 
of infection transmission or rejection as may occur with de-
mineralised bone derived from human cadavers or animal 
sources. Also it gives us a compatible material without any 
rejection or immune reaction against it. So it covers the cases 
where alloplastic materials are contraindicated because of 
rejection or growth restrictions [7]. 
  It has been established that critical size cranial defects 
have been widely used as a model to measure the efficiency 294    The Open Orthopaedics Journal, 2011, Volume 5  Khaled et al. 
of different bone repair techniques. Owing to the fact that 
there is less blood supply, less marrow and thick cortical 
bone in the cranium; so it is hard to repair calvarial bone 
defects. Many studies were done on the critical size cranial 
defects of mouse, rat, rabbit, and other animals [27]. 
  A lot of studies were done to evaluate, standardize and 
justify the optimal technique for bone tissue engineering. In 
China Fulin 2002 and his colleagues [24] studied the use of 
bone marrow derived MSCs seeded coral scaffold in 
reconstruction of mandibular condylar defects in nude mice 
model; where recombinant human bone morphogenetic 
protein-2 (rhBMP2) is used to improve osteoblastic 
phenotype of cultured cells. Successful results were obtained 
after 2 months where the reconstructed bone retained the 
coral shape, which was manipulated to resemble mandibular 
condyle. The use of donor rabbit gives the advantage of 
having an unlimited source for stem cells, but the use of 
nude mice was mandatory to avoid immune reaction as was 
believed. 
 In  2004,  Abukawa et al. [28] evaluated the use of 
autologous bone marrow stem cells to reconstruct 
mandibular defects. Osteoinduction of the stem cells was 
done by the use of -glycerophosphate, dexamethazone and 
ascorbic acid (standard osteo-induction cytokines). This 
study introduced the use of poly-DL-lactic coglycolic acid 
polymer as a biodegradable scaffold that can support tissues 
until new bone was produced. Ever since, biodegradable 
synthetic polyesters were considered as the standard 
scaffolding material in the process of bone tissue 
engineering. Polyesters are completely absorbed after an 
interval of time. This interval is enough for newly formed 
bone to take the function of tissue support. Also polyesters 
can be manipulated as regards the physical properties like 
shape, surface area and porosity. 
 In  2006,  Mankani  et al. [29] used autologous bone 
marrow stem cells in higher animal models to ensure the 
efficiency of bone tissue engineering techniques to 
reconstruct sizable bony defects. Osteo-induction was done 
by the standard osteo-induction cytokines. Calcium 
phosphate ceramics were used as scaffold. These ceramics 
were non-biodegradable materials, which can interfere with 
the mechanical properties of the produced bone. This was 
explained by the fact that the resultant tissue was a 
combination of bone and calcium phosphate ceramics; which 
makes this tissue more fragile than the natural pure bone. 
  They evaluated the characters of the produced bone in 
vivo through ultrasonic examination which showed more 
bone formation than the control areas. Also he commented 
on the mechanical properties of the produced bones which 
were more than the control. Yet he did not compare the 
mechanical properties of the produced bones with the normal 
skull bones; mechanical properties were examined in ex-vivo 
fashion. 
 Once  again  Hou  et al. [27] evaluated autologous bone 
marrow derived MSCs seeded corals with added rhBMP2 in 
reconstruction of New Zealand rabbit calvarial bone defects. 
They compared the results with other equivalent groups 
reconstructed with (1) autologous iliac cortico-cancellous 
bone graft, (2) corals with rhBMP2, (3) rhBMP2 only. The 
produced tissue was evaluated clinically, radiologically and 
histologically. Autologous bone grafts gave the highest 
success rate (84%) with best quality for the produced bone. 
Bone tissue engineering (corals +induced stem cells + 
rhBMP2) gave comparable results with autologous bone 
graft (77.9%). Coral and rhBMP2, and coral only groups 
gave the least results with higher results to the former group. 
  Bone tissue engineering studies have never used allograft 
of MSCs for reconstruction of bone defects. But several 
studies were done in other fields to study the effect of MSCs 
if used as allograft (studies for transplantation immunology). 
Tse and his coworkers [17] studied in vitro immune 
characteristics of human bone marrow derived MSCs. This 
study built up the principles of understanding the immune 
modulating action of MSCs. 
  Basically, MSCs’ phenotype was determined as being 
MHC class I positive and negative for MHC class II; except 
if treated with gamma interferon. MSCs are negative for 
other co-stimulatory antigens (CD80, CD86 and CD40). Tse 
and his coworkers 2003 [17] concluded that this phenotype 
leaves the peripheral blood mononuclear cells anergic with 
no proliferative properties against MSCs or other allogenic 
cells in presence of MSCs. They assumed that this inhibitory 
effect of MSCs isn’t only through direct cellular contact but 
rather through produced diffusible inhibitory factors. This 
was proved by culturing of stimulated proliferating 
mononuclear cells in the same culture with bone marrow 
derived MSCs. The proliferation of the activated 
mononuclear cells was inhibited by the presence of stem 
cells; in spite of the presence of semi-permeable membrane 
in between the two cell populations. 
 Silva  et al. [30] used allograft of MSCs in treatment of 
animal chronic myocardium ischemic model. Results of this 
study showed the effectiveness of this treatment modality 
and commented on the allogenic properties of the stem cells 
used. Surprisingly, the stem cells were completely 
differentiated into vascular endothelial cells and smooth 
muscle cells; where they were successfully engrafted into the 
neo-vasculature induced in the ischemic myocardium. This 
successful engraftment resulted in improvement of cardiac 
vascularity and contractility. No immune suppression drugs 
were used in this study. 
 Matsumoto  et al. [14] went through a more advanced 
study. They used acute myocardium ischemic animal model, 
where bone marrow derived MSCs were transfected with 
vascular endothelial growth factor (VEGF) gene through 
adenovirus vector. These cells were cultured and showed 
progressive increase in the levels of VEGF in the culture 
media. After in vivo injection of these cells inside the acutely 
ischemic hearts models, all experimental animals showed 
improvement of the cardiac vascularity and contractility. 
Radioactive isotope tracing showed that stem cells were 
engrafted successfully in the angiogenesis process and they 
were differentiated in endothelial cells with active 
production of VEGF. 
CONCLUSION 
  Basically, autogenous bone graft is the standard 
technique in reconstruction of bone defects. All alternative 
techniques are aiming to avoid donor site morbidity and 
other complications. Recently bone tissue engineering offers 
a superior technique in management of bone defects. Bone Cell Surface Characterisation  The Open Orthopaedics Journal, 2011, Volume 5    295 
tissue engineering is achieved through three main steps: (1) 
Stem cell harvesting, isolation and expansion. (2) Scaffold 
seeding with osteo-induced stem cells. (3) In vivo re-
implantation. 
  Adult MSCs of bone marrow or adipose tissue origin are 
the standard sources for stem cells used in bone tissue 
engineering. On the other hand, scaffold choice is still under 
investigation in order to be standardized. So bone tissue 
engineering has all the advantages of autogenous bone 
grafting but with no donor site morbidity. Also it can be 
considered as unlimited source of allografts for bone 
reconstruction; as the non immunogenicity character of stem 
cells advocates the idea of stem cells banking. These banked 
cells could be used as an immediate unlimited source for 
bone reconstruction. 
  In conclusion, using bone marrow derived MSCs proved 
to be an efficient technique for bone reconstruction. In spite 
of being allogenic, stem cells were used to manage the 
problematic bone defects. 
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